Blocking CCR5 repolarized the macrophages to exert the anti-tumor efficiency in vitro organoid models, which was further confirmed in a phase I trial of CCR5 antagonist in refractory mCRC patients (128). The gene discussed is CCR5; the disease is neoplasm.